ReviewAsian journal of urology2017
Metabolic syndrome and benign prostatic hyperplasia: An update.
Review in Asian journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review.Prostate cancer and prostatic diseases · 2022Pooled it
- Trial
- Effects of tadalafil on endothelial, angiogenic, metabolic, and microRNA biomarker profiles in sexually active men with BPH and erectile dysfunction: a randomized controlled trial.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Age trumps metabolism: No independent association between lipids, statins, and prostate enlargement in a metabolically controlled cohort.Clinics (Sao Paulo, Brazil) · 2026Article
- Article
- Increased Risk of Recurrent Ischemic Stroke in Male Patients Taking Medications for Benign Prostatic Hyperplasia.Life (Basel, Switzerland) · 2026Article
- Prevalence and association of metabolic syndrome components with benign prostate hyperplasia.Cardiovascular diabetology. Endocrinology reports · 2026Article
- Development and explainability of a machine learning prediction model for histological prostatic inflammation in surgically treated patients with benign prostatic hyperplasia: a single-center internal validation study.Frontiers in medicine · 2026Article
- Molecular Profile and Clinical Associations of Androgen Receptor Coactivators and Structural Genes in Benign Prostatic Hyperplasia and Metabolic Syndrome.Biomedicines · 2025Article
- Association between metabolic syndrome and BPH/LUTS among community-dwelling men in Northern China: a population-based study.BMC urology · 2025Article
- Metabolic syndrome and associated factors among benign prostatic hyperplasia patients at Jimma University Medical center, Jimma, Southwest Ethiopia.Cardiovascular diabetology. Endocrinology reports · 2025Article
- Comorbid Diabetes Mellitus Contributes to Residual Overactive Bladder After Transurethral Surgery for Benign Prostatic Hyperplasia.International journal of urology : official journal of the Japanese Urological Association · 2025Article
- Risk of poor glycemic control in tamsulosin versus finasteride users with type 2 diabetes mellitus.Heliyon · 2025Article
- Oxidative Stress in Benign Prostatic Hyperplasia: Mechanisms, Clinical Relevance and Therapeutic Perspectives.Diseases (Basel, Switzerland) · 2025Review
- Burden of benign prostatic hyperplasia in the Middle East and North Africa Region, 1990-2021.BMC public health · 2025Article
- The Impact of Body Mass Index and Benign Prostatic Hyperplasia on Bone Health of Middle-Aged and Older Men.Obesity science & practice · 2025Article
- Management and Treatment of Benign Prostatic Hyperplasia Symptoms: Current Insights.Research and reports in urology · 2025Review
- Awareness and prevalence of self-reported benign prostatic hyperplasia: a cross-sectional study in Saudi Arabia.Frontiers in public health · 2024Article
- Serum Testosterone and Dihydrotestosterone and Incidence and Progression of Lower Urinary Tract Symptoms: Results From the REDUCE Study.The Journal of urology · 2024Article
- Features of patients referring to the outpatient office due to benign prostatic hyperplasia: analysis of a national prospective cohort of 5815 cases.Prostate cancer and prostatic diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome (MetS) is a cluster of metabolic abnormalities related to central adiposity and insulin resistance. Its importance is increasingly recognized as it associates with increased risks of metabolic and cardiovascular diseases. These metabolic aberrations of MetS may lead to development of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) in men. A 26.5%-55.6% prevalence of MetS in men with LUTS was reported in worldwide studies. Although the exact biological pathway is not clear yet, insulin resistance, increased visceral adiposity, sex hormone alterations and cellular inflammatory reactions played significant roles in the related pathophysiological processes. Clinician should recognize the cardiovascular and metabolic impacts of MetS in men with LUTS, early risk factors optimization and use of appropriate medical therapy may possibly alter or slower the progression of LUTS/BPH, and potentially avoid unnecessary morbidities and mortalities from cardiovascular and metabolic diseases for those men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.